Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.52 |
| ▸ | ITGAV | P06756 | 16/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 1/20 | 0.51 |
| ▸ | ITGB6 | P18564 | 11/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.48 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.48 |
| ▸ | ITGA8 | P53708 | 3/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782067 | 0.90 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGA5MDM2 | |
| SCHEMBL6776952 | 0.90 | ITGB3 (0.49) | ITGB3ITGAVITGB1ITGA5MDM2 | |
| SCHEMBL7835946 | 0.88 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5MDM2 | |
| SCHEMBL242674 | 0.87 | ITGB3 (0.55) | ITGB3ITGAVITGB1ITGA5MDM2 | |
| SCHEMBL7835413 | 0.87 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5MDM2 | |
| SCHEMBL7834572 | 0.87 | ITGB3 (0.48) | ITGB3ITGAVITGB1ITGA5MDM2 | |
| SCHEMBL6777688 | 0.86 | ITGB3 (0.46) | ITGB3ITGAVITGB1ITGA5MDM2 | |
| SCHEMBL6776850 | 0.86 | ITGB3 (0.49) | ITGB3ITGAVITGB1ITGA5MDM2 | |
| SCHEMBL6777182 | 0.85 | RXFP1 (0.52) | ITGB3ITGAVITGB1ITGA5MDM2 | |
| SCHEMBL6778768 | 0.84 | ITGB3 (0.60) | ITGB3ITGAVITGB1ITGA5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | claimed |
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |